RiverPark Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-26,941
Closed -$1.67M 136
2020
Q4
$1.67M Sell
26,941
-3,625
-12% -$223K 0.29% 50
2020
Q3
$1.84M Buy
30,566
+2,836
+10% +$171K 0.41% 45
2020
Q2
$1.63M Buy
27,730
+296
+1% +$17.7K 0.51% 45
2020
Q1
$1.53M Sell
27,434
-16,850
-38% -$1.03M 0.88% 44
2019
Q4
$2.84M Buy
+44,284
New +$2.54M 1.2% 36

Other funds holding BMY

RiverPark Advisors's BMY Position: Q1 2021 in Review

RiverPark Advisors sold out of Bristol-Myers Squibb (BMY) in Q1 2021, closing a stake of 26,941 shares — an estimated $1.67M sold.

RiverPark Advisors first reported a position in BMY in Q4 2019 and held it in 5 quarters. The position peaked at $2.84M in Q4 2019. 2,368 funds tracked by Wall St. Rank hold BMY as of Q1 2021.

  • RiverPark Advisors reported no remaining Bristol-Myers Squibb position as of Q1 2021 after selling out during the quarter.
  • RiverPark Advisors sold 26,941 Bristol-Myers Squibb shares in Q1 2021, an estimated $1.67M.
  • RiverPark Advisors first reported a position in Bristol-Myers Squibb in Q4 2019 and held it in 5 quarters.
  • RiverPark Advisors's Bristol-Myers Squibb position peaked at $2.84M in Q4 2019.
  • 2,368 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2021.

Based on RiverPark Advisors's 13F filing for Q1 2021, filed 17 May 2021.